November 26, 2017 — Arterys Inc. announced the unveiling of their Arterys MICA platform at the 2017 Radiological Society of North America annual meeting (RSNA), Nov. 26-Dec. 1 in Chicago. Visitors to the Arterys Booth will be able to interact with a new portfolio of web-based artificial intelligence (AI) offerings supported by the platform.
Arterys has created Arterys MICA: a novel AI platform for medical image analytics. Today, most imaging interpretation solutions are installed inside hospitals and lack the computing power to deliver real-time, interactive AI insights to medical images, according to the company. Arterys MICA is web-based, and runs on a scalable, distributed GPU architecture. As a result, physicians benefit from vast amounts of computation and can leverage artificial intelligence algorithms instantly.
MICA can support multiple workflows in a variety of imaging modalities, such as magnetic resonance imaging (MRI) and computed tomography (CT). It was designed to work seamlessly with applications that integrate AI algorithms into workflows, allowing clinicians to interact with and edit their output in real time. The system also captures these user edits, so that algorithms can later be improved based on real-world use, creating collective intelligence to benefit all users.
Additionally, MICA includes the Arterys PHI Service, which ensures protected patient data remains within the hospital network, yet it can be accessed remotely by users with the right credentials. This solution achieves scale while protecting patient data privacy. This proprietary technology complies with regional data and privacy laws in the United States, Canada and the European Union.
The cloud provides several additional benefits, including scalability without additional information technology (IT) investment, access to the latest updates and upgrades instantly, and the ability to share images of any size easily and with a complete set of interpretation tools. MICA now supports three applications: the U.S. Food and Drug Administration (FDA)-cleared Cardio AIMR and a new clearance-pending application to support oncology workflow for lung and liver: Arterys Liver AIMR, CT and Arterys Lung AICT.
Demonstrations of the FDA-clearance pending oncology workflows will also be available. Supported by MICA, these products have been designed to volumetrically segment and measure suspicious lesions, help track them over time and allow clinicians to apply radiological standards such as LI-RADS and Lung-RADS as appropriate.
At the Machine Learning Showcase, Arterys CEO Fabien Beckers and Albert Hsiao, M.D., Ph.D., will present "A Year of Experience with AI in the Market: What We've Learned and the Future of Medical Imaging and Cloud AI," and offer anecdotes, learnings and insights from a year of on-market experience with AI, followed by discussion of the role cloud AI will play.
For more information: www.arterys.com
September 24, 2026 
